StockWatch
·

R Systems International Limited Q1 FY27 Results

RSYSTEMSQ1 FY27 Results
Filing
Result:Good· Market: DownBase effectMargin expansion

Outlook: Cautiously Optimistic · Guidance: None

MetricValueQ4 FY26Q1 FY26
Revenue601.70 Cr4.7%30.2%
Total Income603.07 Cr1.4%18.5%
Expenditure522.56 Cr3.4%27.5%
PBT80.51 Cr10.2%18.8%
Net Profit55.57 Cr15.1%26.7%
OPM18.39%0.89pp3.20pp
NPM9.21%1.79pp5.69pp
EPS4.6915.0%26.8%
View full financials

IT-sector core metrics are strong — revenue +30.2% YoY and OPM expanded ~320bps (15.2%→18.4%) — with the reported 26.7% PAT decline purely a base-effect artifact from an outsized ₹47cr one-off other income last year (adjusted PBT actually up ~50%).

R SYSTEMS INTERNATIONAL · Q1 FY-2027 · THE VERDICT

Revenue +30%, profit −27%: the FX one-time that explains the gap

Reported profit fell 26.7% YoY despite revenue surging 30.2%. An ₹18 crore FX hedging gain boosts the headline, but adjusted profit (+35.4%) and the underlying margin picture tell a different story—one of slowing organic growth and FX-dependent margins.

17 Aug 2026 · 6 min read
Reported Revenue

₹601.7 Cr

+30.2% YoY

Reported PAT

₹55.6 Cr

−26.7% YoY

Adjusted PAT

₹62.9 Cr

+35.4% YoY

EBITDA Margin

20.1%

FX-dependent; guided 18–19% sustainable

The quarter opens with a paradox: revenue rocketed 30.2% to ₹601.7 crore, yet reported net profit fell 26.7% to ₹55.6 crore. But adjust for one-time items—an ₹18 crore FX hedging gain and ₹6.2 crore in RSU expenses—and adjusted PAT emerges at ₹62.9 crore, up 35.4% YoY. The real question: which number matters for a holder?

Where profit and revenue diverged

Revenue benefited from three tailwinds: organic volume growth, the Novigo acquisition, and rupee depreciation (a material currency boost that management explicitly acknowledged). On the profit side, reported PAT lagged because of the ₹18 crore FX hedging reclassification—a one-time item excluded from adjusted profit. Strip the one-time noise, and adjusted profit is +35.4% YoY, a respectable organic performance. But the adjusted figure comes with an asterisk: it excludes RSU expenses and non-recurring items, so its sustainability depends on whether those items recur.

Management claims vs. what holds up

Record revenue crossing Rs 600 crores with strong EBITDA margins

Overstated

Revenue ₹601.7 Cr (+30.2% YoY), EBITDA 20.1%. Reported PAT fell 26.7% YoY; margins are FX-dependent and management guided 18–19% sustainable.

Adjusted net profit up 35.4% YoY

Supported

Adjusted PAT ₹62.9 Cr (+35.4% YoY), excluding RSU ₹6.2 Cr and FX hedging one-time items. Organic profit solid on this basis.

18% quarter-on-quarter revenue growth without headcount increase

Supported

Revenue ₹601.7 Cr vs. ₹574.8 Cr in prior quarter = 4.7% QoQ in INR, 1.2% in USD. 18% is YoY, not QoQ.

TTM ACV bookings at $82.9M, continuing strong deal momentum

Overstated

TTM ACV $82.9M, essentially flat QoQ (up $0.6M). Bookings not accelerating despite 5 named large deal wins.

Consistent organic growth quarter-over-quarter

Contradicted

QoQ revenue growth 4.7% in INR; constant-currency growth ~2%, half the 3–4% target. Analyst Ashis Das flagged as 'very muted.'

What changed on this call

Deal quality upgraded. Management named 5 large wins (telecom, fintech, insurance, financial services, ad-tech) and highlighted improving average deal size and contract duration. The AI-first narrative is gaining traction, and the HFS Horizon 2 GCC Accelerator recognition validates the differentiation strategy.

Organic growth execution downgraded. Despite optimistic messaging, constant-currency growth remains stuck at ~2%, less than half the 3–4% target. Management attributed delays to macro uncertainty and client decision-cycle lengthening but offered no catalyst timeline to bridge the gap.

ACV momentum flat. TTM bookings at $82.9M vs. $82.3M in Q1 FY-2027 (up $0.6M, essentially flat QoQ). Management relies on a 'lag effect'—H1 wins converting to H2 revenue—but the Q2 bookings don't yet show acceleration. Conversion timing and rate uncertain.

SG&A investment sharply increased. Deliberate spend-up: CRO hired, AI and domain experts added to sales, EXIQO AI studio brand launch. Management is betting on organizational muscle to drive pipeline conversion, but the ROI is execution-dependent.

Margin sustainability framed as FX-dependent. Management explicitly guided 18–19% adjusted EBITDA as the sustainable range, acknowledging that rupee depreciation is 'beyond our control' and a material contributor to the 20.1% reported margin. When FX winds reverse, margins will face 100–200 bps of headwind.

Earnings quality: three red flags

The bull-bear ledger
  • Revenue +30.2% YoY; strong volume growth and deal wins

  • Adjusted PAT +35.4% YoY; organic profit growing

  • Deal quality improving; 5 named large wins; average deal size and duration up

  • EBITDA margins stable at 20.1%; EXIQO AI studio delivering 2x productivity gains

  • Reported PAT fell 26.7% YoY; heavily dependent on ₹18 Cr one-time FX gain

  • Constant-currency organic growth stuck at ~2%, half the 3–4% target

  • ACV bookings flat QoQ at $82.9M; no acceleration despite large deal wins

  • Margins are FX-dependent; normalized margin likely 100–200 bps lower

  • Adjusted profit narrative relies on RSU exclusion and FX reclassification; earnings quality concerns

Risks, ranked by what should concern a holder

Constant-currency organic growth gap (2% vs. 3–4% target)

High

This is the core of the investment thesis. If CC growth stays at ~2% despite improved deal quality and organizational changes, the strategy execution is at risk. Management offered no catalyst timeline. Bridging this gap is non-negotiable.

Margin sustainability and FX dependency

High

20.1% EBITDA includes material rupee depreciation tailwind. Management explicitly guided 18–19% sustainable, implying 100–200 bps of FX benefit. When rupee stabilizes or appreciates, margins will compress. Wage hikes and SG&A investment will add pressure.

Adjusted vs. reported profit divergence

Medium

Adjusted PAT is the headline (+35.4%), but reported PAT fell 26.7%. The gap comes from FX hedging and RSU adjustments. Street may penalize selective metric highlighting or view adjusted figures as non-sustainable.

Organic growth acceleration unproven

Medium

Despite organizational changes (CRO hire, AI experts, EXIQO launch), CC growth remains stuck at ~2%. No proof point that the investments will translate to revenue acceleration.

Booking-to-revenue conversion lag

Medium

5 named large deal wins announced, but ACV bookings flat QoQ at $82.9M. Management relies on 'lag effect' (H1 wins → H2 revenue), but this hasn't shown in the booking numbers yet. Conversion timing uncertain.

How the street is positioned

Post-result price action speaks skepticism. The stock fell 4.6% on day 1 (delivery 48.9%), faded to −7.96% by day 3, and widened to −9.44% by day 5. The initial pop didn't hold, suggesting the market found the adjusted-profit narrative and organic-growth weakness unconvincing. This is a contrarian signal: the market is repricing on execution risk, not valuation.

Deep drawdown from ATH; below all key averages. At ₹241.8, the stock is 44.5% below its all-time high of ₹435.9 and trading below its 20-day (₹252.41), 50-day (₹248.63), and 200-day (₹316.38) moving averages. The RSI of 41.2 is neutral, neither oversold nor overbought. The positioning suggests the market has already repriced for execution risk, and further downside may be limited if the company can prove CC growth acceleration in H2.

Institutional flows turning cautious. FII holdings are stable but near multi-quarter lows at 3.82% (up just 6 bps QoQ). DII holdings fell 207 bps QoQ to 6.53%, indicating domestic institutional trimming. This is not a vote of confidence; it suggests institutions are waiting for proof of execution before re-engaging.

Bulk/block trading quiet. No insider-linked selling near the highs, but volume trend is decreasing overall. The lack of significant bulk activity suggests limited conviction on either side of the trade—holders are neutral, and new buyers are cautious.

What to watch next

The three things that reset the debate in H2 FY-2027
  • 1 · Constant-currency growth acceleration

    Can management bridge from ~2% to the 3–4% target in H2? This is the linchpin. If CC growth stays at 2%, the AI narrative and deal-quality improvements don't offset the execution miss. Watch for Q3 constant-currency revenue growth rate and management commentary on decision-cycle timing.

  • 2 · ACV bookings and large-deal conversion

    Five named deals (telecom, fintech, insurance, financial services, ad-tech) should materialize as bookings and revenue. If ACV bookings stay flat or decline in Q3 despite these wins, conversion risk escalates. Watch TTM ACV trend and management's confidence in deal-win velocity.

  • 3 · Margin normalization and cost pressure

    When FX winds reverse (rupee appreciates), will EBITDA margins hold above the guided 18–19%? Wage hikes and SG&A investment (CRO, AI experts, EXIQO marketing) will add cost pressure. Watch quarterly adjusted EBITDA % trend and management's confidence in the sustainable 18–19% range as a floor.

R Systems is executing a sound strategy on AI-first transformation and legacy modernization. Revenue growth is real, deal quality is improving, and market recognition (HFS award) is validating the differentiation. But this quarter shows a company where strategy and positioning are intact while execution on near-term organic growth falls short. Adjusted profit is a useful lens for understanding operational performance, but reported profit weakness and FX-dependent margins raise earnings-quality concerns that the market is rightly penalizing.

The stock's 44.5% drawdown from ATH and down 9.4% post-result suggest institutional skepticism on execution. The day-5 decline, rather than a sustained pop, is the market's own verdict: revenue growth doesn't substitute for constant-currency growth acceleration and earnings durability.

For a holder, this quarter is a test of patience: steady strategy execution, mixed near-term results. The number to track from here is constant-currency organic growth. If R Systems bridges from ~2% to 3–4% in H2, the bull case gains traction and re-rating is likely. If it doesn't, the AI pivot remains a quality long-term thesis on weaker near-term execution, and the stock faces further pressure until organic growth inflects. The verdict: Hold, pending proof of acceleration.

Informational and educational content only. Not investment advice.